Annovis Bio, Inc. (ANVS) stock
ANVSNYSEPharmaceutical PreparationsFiscal year ends December 31
$0.74−0.01 (-0.91%)
Close on Nov 17, 2026Market cap $31.66MP/E –Yield –
Annovis Bio operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Annovis Bio's operating income for the twelve months ending Jun 30, 2026 was -$49.53M. For fiscal 2025 it was -$29.70M. The highest annual figure on record is -$1.61M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$29.70M | – |
| FY2024 | Dec 31, 2024 | -$26.69M | – |
| FY2023 | Dec 31, 2023 | -$45.04M | – |
| FY2022 | Dec 31, 2022 | -$25.51M | – |
| FY2021 | Dec 31, 2021 | -$14.54M | – |
| FY2020 | Dec 31, 2020 | -$6.64M | – |
| FY2019 | Dec 31, 2019 | -$1.61M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$14.38M | – |
| Q1 FY2026 | Mar 31, 2026 | -$18.01M | – |
| Q4 FY2025 | Dec 31, 2025 | -$9.71M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.43M | – |
| Q2 FY2025 | Jun 30, 2025 | -$6.27M | – |
| Q1 FY2025 | Mar 31, 2025 | -$6.28M | – |
| Q4 FY2024 | Dec 31, 2024 | -$6.73M | – |
| Q3 FY2024 | Sep 30, 2024 | -$4.39M | – |
| Q2 FY2024 | Jun 30, 2024 | -$7.76M | – |
| Q1 FY2024 | Mar 31, 2024 | -$7.81M | – |
| Q4 FY2023 | Dec 31, 2023 | -$10.44M | – |
| Q3 FY2023 | Sep 30, 2023 | -$14.86M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.76M | – |
| Q1 FY2023 | Mar 31, 2023 | -$9.97M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.80M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.48M | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.97M | – |
| Q1 FY2022 | Mar 31, 2022 | -$5.25M | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.92M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.85M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.53M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.23M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.91M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.60M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.54M | – |
| Q1 FY2020 | Mar 31, 2020 | -$583.16K | – |
| Q4 FY2019 | Dec 31, 2019 | -$870.96K | – |
| Q3 FY2019 | Sep 30, 2019 | -$241.79K | – |
| Q2 FY2019 | Jun 30, 2019 | -$306.08K | – |
| Q1 FY2019 | Mar 31, 2019 | -$186.79K | – |
See a number that looks wrong?